Study S002623

A Phase I, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of HDM1002 on the Pharmacokinetics of Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy and Overweight Adult Chinese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06601517
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: UNKNOWN
Enrollment: 30
Start: 2024-10
Primary completion: 2025-02
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Healthy Adult Subject; Overweight Subject
Interventions: DRUG:Repaglinide; DRUG:Atorvastatin; DRUG:Digoxin; DRUG:Rosuvastatin; DRUG:HDM1002
Results posted: FALSE

Registered primary outcomes

AUC[0-∞] [Period 1 and Period 3: Day 1-Day 16]
AUC[0-t] [Period 1 and Period 3: Day 1-Day 16]
Cmax [Period 1 and Period 3: Day 1-Day 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.